Clinical trial · Observational
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women in the Kingdom of Bahrain
NCT01205412CI-TRIAL-00008529completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for post-natal check up in the Kingdom of Bahrain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papillomavirus Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endocervical samples | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Assessed Cohort
- description
- Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
- interventionNames
- Procedure: Endocervical samples
Primary outcomes (1)
- measure
- Prevalence of any Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) and HPV type distribution among women undergoing cervical sample testing and post-natal check up.
- timeFrame
- Average time frame: 12 months
Secondary outcomes (3)
- measure
- Prevalence of any HPV DNA and HPV type distribution among women of different age strata undergoing cervical sample testing and post-natal check up.
- timeFrame
- Average time frame: 12 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Women ≥ 20 years of age attending a clinic for routine cervical screening OR * Women ≥ 16 years of age presenting for post-natal check-ups * Women providing a cervical sample * Written informed consent or oral-witnessed thumb printed informed consent obtained from the subject Exclusion Criteria: * Referral for abnormal cervical sample at the current visit * Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (Note: Enrolment can be delayed until this condition is resolved) * Pregnant women * History of hysterectomy * Known diagnosis of immunosuppression, or patient on immunosuppressives * Having received one or more doses of human papillomavirus vaccine prior to participating in the study
References
Publications (1)
- DERIVEDMoosa K, Alsayyad AS, Quint W, Gopala K, DeAntonio R. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014 Dec 3;14:905. doi: 10.1186/1471-2407-14-905. PMID 25466757